CDIPT

Across TCGA pan-cancer cohorts, CDIPT mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CDIPT data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CDIPT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDIPT expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, UCEC, and GBM are the cancer types where CDIPT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.878	0.686	.003	50	view →
UCEC	DFS	Quartile	II,III,IV	0.311	1.000	.006	36	view →
GBM	DFS	Tertile	All	0.621	0.281	<.001	16	view →
COAD	DFS	Median	III,IV	0.829	1.000	.027	12	view →
CCRCC	DFS	Tertile	All	0.919	0.433	.003	11	view →
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	5	view →
LUAD	OS	Tertile	III,IV	0.876	0.287	.042	2	view →
PDAC	OS	Median	II,III,IV	0.584	0.398	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CDIPT–HNSC (DFS)

Open the HNSC breakdown →